Lytix Biopharma reports promising clinical results for ruxotemitide in melanoma and basal cell carcinoma

Reuters11-18

Lytix Biopharma reports promising clinical results for ruxotemitide in melanoma and basal cell carcinoma

Cash and short-term financial investments at Lytix Biopharma AS amounted to NOK 90.0 million as of September 30, 2025. The reported net loss was temporarily increased by a non-cash share option expense of NOK 11.9 million related to a new option program launched in September. During the period, Lytix advanced ruxotemitide toward commercialization through internal work in neoadjuvant melanoma and a partnership with Verrica Pharmaceuticals for the non-surgical treatment of basal cell carcinoma. The company is also expanding into deep-seated tumors with LTX-401, supported by positive pre-clinical data and regulatory feedback, and is developing a strategic plan for further clinical development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lytix Biopharma AS published the original content used to generate this news brief via Cision (Ref. ID: 20251117:BIT:1662:0) on November 18, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2584983010?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-18 14:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584983010","market":"nz","top_or_hot":-1,"title":"Lytix Biopharma reports promising clinical results for ruxotemitide in melanoma and basal cell carcinoma","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lytix Biopharma reports promising clinical results for ruxotemitide in melanoma and basal cell carcinoma\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cash and short-term financial investments at Lytix Biopharma AS amounted to NOK 90.0 million as of September 30, 2025. The reported net loss was temporarily increased by a non-cash share option expense of NOK 11.9 million related to a new option program launched in September. During the period, Lytix advanced ruxotemitide toward commercialization through internal work in neoadjuvant melanoma and a partnership with Verrica Pharmaceuticals for the non-surgical treatment of basal cell carcinoma. The company is also expanding into deep-seated tumors with LTX-401, supported by positive pre-clinical data and regulatory feedback, and is developing a strategic plan for further clinical development.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lytix Biopharma AS published the original content used to generate this news brief via Cision (Ref. ID: 20251117:BIT:1662:0) on November 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lytix Biopharma reports promising clinical results for ruxotemitide in melanoma and basal cell carcinoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLytix Biopharma reports promising clinical results for ruxotemitide in melanoma and basal cell carcinoma\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-18 14:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lytix Biopharma reports promising clinical results for ruxotemitide in melanoma and basal cell carcinoma\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cash and short-term financial investments at Lytix Biopharma AS amounted to NOK 90.0 million as of September 30, 2025. The reported net loss was temporarily increased by a non-cash share option expense of NOK 11.9 million related to a new option program launched in September. During the period, Lytix advanced ruxotemitide toward commercialization through internal work in neoadjuvant melanoma and a partnership with Verrica Pharmaceuticals for the non-surgical treatment of basal cell carcinoma. The company is also expanding into deep-seated tumors with LTX-401, supported by positive pre-clinical data and regulatory feedback, and is developing a strategic plan for further clinical development.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lytix Biopharma AS published the original content used to generate this news brief via Cision (Ref. ID: 20251117:BIT:1662:0) on November 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL7VXFbS:1","article_id":"2584983010","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584983010","pubTimestamp":1763445652,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cash and short-term financial investments at Lytix Biopharma AS amounted to NOK 90.0 million as of September 30, 2025. The reported net loss was temporarily increased by a non-cash share option expense of NOK 11.9 million related to a new option program launched in September. During the period, Lytix advanced ruxotemitide toward commercialization through internal work in neoadjuvant melanoma and a partnership with Verrica Pharmaceuticals for the non-surgical treatment of basal cell carcinoma. The company is also expanding into deep-seated tumors with LTX-401, supported by positive pre-clinical data and regulatory feedback, and is developing a strategic plan for further clinical development.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","VRCA":"Verrica Pharmaceuticals Inc."},"translate_title":"Lytix Biopharma报告ruxotemitide治疗黑色素瘤和基底细胞癌的有希望的临床结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VRCA":0.9},"content_text":"Lytix Biopharma reports promising clinical results for ruxotemitide in melanoma and basal cell carcinoma\n    \n\n        Cash and short-term financial investments at Lytix Biopharma AS amounted to NOK 90.0 million as of September 30, 2025. The reported net loss was temporarily increased by a non-cash share option expense of NOK 11.9 million related to a new option program launched in September. During the period, Lytix advanced ruxotemitide toward commercialization through internal work in neoadjuvant melanoma and a partnership with Verrica Pharmaceuticals for the non-surgical treatment of basal cell carcinoma. The company is also expanding into deep-seated tumors with LTX-401, supported by positive pre-clinical data and regulatory feedback, and is developing a strategic plan for further clinical development.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lytix Biopharma AS published the original content used to generate this news brief via Cision (Ref. ID: 20251117:BIT:1662:0) on November 18, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2584983010","isCrawlerRequest":true}